MARKER THERAPEUTICS INC (MRKR) Stock News

USA - NASDAQ:MRKR - US57055L2060 - Common Stock

1.04 USD

-0.02 (-1.89%)

Last: 10/15/2025, 2:45:05 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

MRKR Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Marker Therapeutics

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

2 months ago - By: Marker Therapeutics

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

2 months ago - By: Benzinga

Marker Therapeutics Stock Drops After Report About Lymphoma Treatment

2 months ago - By: Marker Therapeutics

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

a year ago - By: BusinessInsider

News Image

MRKR Stock Earnings: Marker Therapeutics Beats EPS for Q2 2024

a year ago - By: InvestorPlace

MRKR Stock Earnings: Marker Therapeutics Beats EPS for Q2 2024

a year ago - By: InvestorPlace

MRKR Stock Earnings: Marker Therapeutics Reported Results for Q4 2023

3 months ago - By: Benzinga - Mentions: CDNA CLSD WINT OVID ...

12 Health Care Stocks Moving In Thursday's Intraday Session

a year ago - By: BusinessInsider

News Image

MRKR Stock Earnings: Marker Therapeutics Reported Results for Q1 2024

a year ago - By: InvestorPlace

MRKR Stock Earnings: Marker Therapeutics Reported Results for Q1 2024

4 months ago - By: Marker Therapeutics

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

5 months ago - By: Marker Therapeutics

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

5 months ago - By: Marker Therapeutics

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

7 months ago - By: Marker Therapeutics

Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference

7 months ago - By: Marker Therapeutics

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

8 months ago - By: Marker Therapeutics

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

10 months ago - By: Marker Therapeutics

Marker Therapeutics Announces $16.1 Million Private Placement

10 months ago - By: Marker Therapeutics

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

10 months ago - By: Marker Therapeutics

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

10 months ago - By: Marker Therapeutics

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

a year ago - By: Marker Therapeutics

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

a year ago - By: Marker Therapeutics

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

a year ago - By: Marker Therapeutics

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

a year ago - By: Marker Therapeutics

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma

a year ago - By: Marker Therapeutics

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

2 years ago - By: Marker Therapeutics

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

2 years ago - By: Marker Therapeutics

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

2 years ago - By: Marker Therapeutics

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

2 years ago - By: Marker Therapeutics

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601